Zoetis Inc. Selling, General and Administrative Expense
Zoetis Inc. (ZTS) reported Selling, General and Administrative Expense of $592.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Zoetis Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $592.00M, a 3.58% decline year-over-year.
- Zoetis Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $588.00M, a 2.44% increase year-over-year.
- Zoetis Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $619.00M, a 0.96% decline year-over-year.
- Zoetis Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $579.00M, a 2.48% increase year-over-year.
- Zoetis Inc. selling, general and administrative expense for fiscal 2025 was $2.38B, a 2.59% increase from fiscal 2024.
- Zoetis Inc. selling, general and administrative expense for fiscal 2024 was $2.32B, a 7.76% increase from fiscal 2023.
- Zoetis Inc. selling, general and administrative expense for fiscal 2023 was $2.15B, a 7.07% increase from fiscal 2022.
- Zoetis Inc. selling, general and administrative expense for fiscal 2022 was $2.01B, a 0.40% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $592.00M 10-Q · filed 2026-08-06 | $1.18B 10-Q · filed 2026-08-06 | $1.80B derived: sum of 3 quarters · filed 2026-08-06 | $2.38B derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $588.00M 10-Q · filed 2026-05-07 | $1.21B derived: sum of 2 quarters · filed 2026-05-07 | $1.79B derived: sum of 3 quarters · filed 2026-05-07 | $2.40B derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $619.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.20B derived: sum of 2 quarters · filed 2026-02-12 | $1.81B derived: sum of 3 quarters · filed 2026-08-06 | $2.38B 10-K · filed 2026-02-12 | ||
| 2025-09-30 | $579.00M 10-Q · filed 2025-11-04 | $1.19B derived: sum of 2 quarters · filed 2026-08-06 | $1.76B 10-Q · filed 2025-11-04 | $2.39B derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $614.00M 10-Q · filed 2026-08-06 | $617.00M 10-Q · filed 2025-08-05 | $1.19B 10-Q · filed 2026-08-06 | $1.18B 10-Q · filed 2025-08-05 | $1.81B derived: sum of 3 quarters · filed 2026-08-06 | $2.38B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $574.00M 10-Q · filed 2026-05-07 | $563.00M 10-Q · filed 2025-05-06 | $1.20B derived: sum of 2 quarters · filed 2026-05-07 | $1.76B derived: sum of 3 quarters · filed 2026-05-07 | $2.35B derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $625.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.19B derived: sum of 2 quarters · filed 2026-02-12 | $1.77B derived: sum of 3 quarters · filed 2026-02-12 | $2.32B 10-K · filed 2026-02-12 | ||
| 2024-09-30 | $565.00M 10-Q · filed 2025-11-04 | $1.15B derived: sum of 2 quarters · filed 2025-11-04 | $1.69B 10-Q · filed 2025-11-04 | $2.26B derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-06-30 | $581.00M 10-Q · filed 2025-08-05 | $1.13B 10-Q · filed 2025-08-05 | $1.69B derived: sum of 3 quarters · filed 2026-02-12 | $2.22B derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-03-31 | $547.00M 10-Q · filed 2025-05-06 | $1.11B derived: sum of 2 quarters · filed 2026-02-12 | $1.64B derived: sum of 3 quarters · filed 2026-02-12 | $2.19B derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2023-12-31 | $565.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.09B derived: sum of 2 quarters · filed 2026-02-12 | $1.65B derived: sum of 3 quarters · filed 2026-02-12 | $2.15B 10-K · filed 2026-02-12 | ||
| 2023-09-30 | $525.00M 10-Q · filed 2024-11-04 | $1.08B derived: sum of 2 quarters · filed 2024-11-04 | $1.59B 10-Q · filed 2024-11-04 | $2.10B derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-06-30 | $556.00M 10-Q · filed 2024-08-06 | $1.06B 10-Q · filed 2024-08-06 | $1.57B derived: sum of 3 quarters · filed 2025-02-13 | $2.08B derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-03-31 | $505.00M 10-Q · filed 2024-05-02 | $1.02B derived: sum of 2 quarters · filed 2025-02-13 | $1.52B derived: sum of 3 quarters · filed 2025-02-13 | $2.05B derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2022-12-31 | $514.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $1.01B derived: sum of 2 quarters · filed 2025-02-13 | $1.54B derived: sum of 3 quarters · filed 2025-02-13 | $2.01B 10-K · filed 2025-02-13 | ||
| 2022-09-30 | $501.00M 10-Q · filed 2023-11-02 | $1.03B derived: sum of 2 quarters · filed 2023-11-02 | $1.50B 10-Q · filed 2023-11-02 | $2.09B derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-06-30 | $529.00M 10-Q · filed 2023-08-08 | $994.00M 10-Q · filed 2023-08-08 | $1.59B derived: sum of 3 quarters · filed 2024-02-13 | $2.09B derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-03-31 | $465.00M 10-Q · filed 2023-05-04 | $1.06B derived: sum of 2 quarters · filed 2024-02-13 | $1.56B derived: sum of 3 quarters · filed 2024-02-13 | $2.06B derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2021-12-31 | $593.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $1.10B derived: sum of 2 quarters · filed 2024-02-13 | $1.59B derived: sum of 3 quarters · filed 2024-02-13 | $2.00B 10-K · filed 2024-02-13 | ||
| 2021-09-30 | $504.00M 10-Q · filed 2022-11-03 | $999.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.41B 10-Q · filed 2022-11-03 | $1.93B derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-06-30 | $495.00M 10-Q · filed 2022-08-04 | $904.00M 10-Q · filed 2022-08-04 | $1.42B derived: sum of 3 quarters · filed 2023-02-14 | $1.85B derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-03-31 | $409.00M 10-Q · filed 2022-05-05 | $929.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.35B derived: sum of 3 quarters · filed 2023-02-14 | $1.75B derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2020-12-31 | $520.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $944.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.34B derived: sum of 3 quarters · filed 2023-02-14 | $1.73B 10-K · filed 2023-02-14 | ||
| 2020-09-30 | $424.00M 10-Q · filed 2021-11-04 | $817.00M derived: sum of 2 quarters · filed 2021-11-04 | $1.21B 10-Q · filed 2021-11-04 | $1.68B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2020-06-30 | $393.00M 10-Q · filed 2021-08-05 | $782.00M 10-Q · filed 2021-08-05 | $1.25B derived: sum of 3 quarters · filed 2022-02-15 | $1.65B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2020-03-31 | $389.00M 10-Q · filed 2021-05-06 | $861.00M derived: sum of 2 quarters · filed 2022-02-15 | $1.25B derived: sum of 3 quarters · filed 2022-02-15 | $1.66B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2019-12-31 | $472.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $863.00M derived: sum of 2 quarters · filed 2022-02-15 | $1.27B derived: sum of 3 quarters · filed 2022-02-15 | $1.64B 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $391.00M 10-Q · filed 2020-11-05 | $797.00M derived: sum of 2 quarters · filed 2020-11-05 | $1.17B 10-Q · filed 2020-11-05 | $1.59B derived: sum of 4 quarters · filed 2021-02-16 | ||
| 2019-06-30 | $406.00M 10-Q · filed 2020-08-06 | $775.00M 10-Q · filed 2020-08-06 | $1.20B derived: sum of 3 quarters · filed 2021-02-16 | $1.56B derived: sum of 4 quarters · filed 2021-02-16 | ||
| 2019-03-31 | $369.00M 10-Q · filed 2020-05-06 | $789.00M derived: sum of 2 quarters · filed 2021-02-16 | $1.16B derived: sum of 3 quarters · filed 2021-02-16 | $1.51B derived: sum of 4 quarters · filed 2021-02-16 | ||
| 2018-12-31 | $420.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $787.00M derived: sum of 2 quarters · filed 2021-02-16 | $1.15B derived: sum of 3 quarters · filed 2021-02-16 | $1.48B 10-K · filed 2021-02-16 | ||
| 2018-09-30 | $367.00M 10-Q · filed 2019-11-07 | $726.00M derived: sum of 2 quarters · filed 2019-11-07 | $1.06B 10-Q · filed 2019-11-07 | $1.43B derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-06-30 | $359.00M 10-Q · filed 2019-08-06 | $697.00M 10-Q · filed 2019-08-06 | $1.06B derived: sum of 3 quarters · filed 2020-02-13 | $1.39B derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-03-31 | $338.00M 10-Q · filed 2019-05-02 | $699.00M derived: sum of 2 quarters · filed 2020-02-13 | $1.03B derived: sum of 3 quarters · filed 2020-02-13 | $1.36B derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2017-12-31 | $361.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $689.00M derived: sum of 2 quarters · filed 2020-02-13 | $1.02B derived: sum of 3 quarters · filed 2020-02-13 | $1.33B 10-K · filed 2020-02-13 | ||
| 2017-10-01 | $328.00M 10-Q · filed 2018-11-01 | $664.00M derived: sum of 2 quarters · filed 2018-11-01 | $973.00M 10-Q · filed 2018-11-01 | $1.33B derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2017-07-02 | $336.00M 10-Q · filed 2018-08-02 | $645.00M 10-Q · filed 2018-08-02 | $1.01B derived: sum of 3 quarters · filed 2019-02-14 | $1.35B derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2017-04-02 | $309.00M 10-Q · filed 2018-05-02 | $670.00M derived: sum of 2 quarters · filed 2019-02-14 | $1.01B derived: sum of 3 quarters · filed 2019-02-14 | $1.36B derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2016-12-31 | $361.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $706.00M derived: sum of 2 quarters · filed 2019-02-14 | $1.05B derived: sum of 3 quarters · filed 2019-02-14 | $1.36B 10-K · filed 2019-02-14 | ||
| 2016-10-02 | $345.00M 10-Q · filed 2017-11-02 | $688.00M derived: sum of 2 quarters · filed 2017-11-02 | $1.00B 10-Q · filed 2017-11-02 | $1.43B derived: sum of 4 quarters · filed 2018-02-15 | ||
| 2016-07-03 | $343.00M 10-Q · filed 2017-08-08 | $658.00M 10-Q · filed 2017-08-08 | $1.08B derived: sum of 3 quarters · filed 2018-02-15 | $1.46B derived: sum of 4 quarters · filed 2018-02-15 | ||
| 2016-04-03 | $315.00M 10-Q · filed 2017-05-04 | $740.00M derived: sum of 2 quarters · filed 2018-02-15 | $1.11B derived: sum of 3 quarters · filed 2018-02-15 | $1.49B derived: sum of 4 quarters · filed 2018-02-15 | ||
| 2015-12-31 | $425.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $799.00M derived: sum of 2 quarters · filed 2018-02-15 | $1.18B derived: sum of 3 quarters · filed 2018-02-15 | $1.53B 10-K · filed 2018-02-15 | ||
| 2015-09-27 | $374.00M 10-Q · filed 2016-11-03 | $753.00M derived: sum of 2 quarters · filed 2016-11-03 | $1.11B 10-Q · filed 2016-11-03 | $1.60B derived: sum of 4 quarters · filed 2017-02-16 | ||
| 2015-06-28 | $379.00M 10-Q · filed 2016-08-05 | $733.00M 10-Q · filed 2016-08-05 | $1.23B derived: sum of 3 quarters · filed 2017-02-16 | $1.62B derived: sum of 4 quarters · filed 2017-02-16 | ||
| 2015-03-29 | $354.00M 10-Q · filed 2016-05-06 | $851.00M derived: sum of 2 quarters · filed 2017-02-16 | $1.25B derived: sum of 3 quarters · filed 2017-02-16 | $1.64B derived: sum of 4 quarters · filed 2017-02-16 | ||
| 2014-12-31 | $497.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $891.00M derived: sum of 2 quarters · filed 2017-02-16 | $1.29B derived: sum of 3 quarters · filed 2017-02-16 | $1.64B 10-K · filed 2017-02-16 | ||
| 2014-09-28 | $394.00M 10-Q · filed 2015-11-05 | $790.00M derived: sum of 2 quarters · filed 2015-11-05 | $1.15B 10-Q · filed 2015-11-05 | $1.60B derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-06-29 | $396.00M 10-Q · filed 2015-08-06 | $752.00M 10-Q · filed 2015-08-06 | $1.21B derived: sum of 3 quarters · filed 2016-02-24 | $1.61B derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-03-30 | $356.00M 10-Q · filed 2015-05-07 | $814.00M derived: sum of 2 quarters · filed 2016-02-24 | $1.21B derived: sum of 3 quarters · filed 2016-02-24 | $1.61B derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2013-12-31 | $458.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $857.00M derived: sum of 2 quarters · filed 2016-02-24 | $1.26B derived: sum of 3 quarters · filed 2016-02-24 | $1.61B 10-K · filed 2016-02-24 | ||
| 2013-09-29 | $399.00M 10-Q · filed 2014-11-10 | $798.00M derived: sum of 2 quarters · filed 2014-11-10 | $1.16B 10-Q · filed 2014-11-10 | $1.61B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | $399.00M 10-Q · filed 2014-08-12 | $756.00M 10-Q · filed 2014-08-12 | $1.21B derived: sum of 3 quarters · filed 2015-02-27 | $1.54B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $357.00M 10-Q · filed 2014-05-13 | $810.00M derived: sum of 2 quarters · filed 2015-02-27 | $1.15B derived: sum of 3 quarters · filed 2015-02-27 | $1.49B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2012-12-31 | $453.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $788.00M derived: sum of 2 quarters · filed 2015-02-27 | $1.13B derived: sum of 3 quarters · filed 2015-02-27 | $1.47B 10-K · filed 2015-02-27 | ||
| 2012-09-30 | $335.00M 10-Q · filed 2013-11-13 | $679.00M derived: sum of 2 quarters · filed 2013-11-13 | $1.02B 10-Q · filed 2013-11-13 | |||
| 2012-07-01 | $344.00M 10-Q · filed 2013-08-14 | $682.00M 10-Q · filed 2013-08-14 | ||||
| 2012-04-01 | $338.00M 10-Q · filed 2013-05-15 | |||||
| 2011-12-31 | $1.45B 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |